---
title: "HUAPONT LIFE SCIENCES hit the limit down, reaching a new low in over 4 months, with an annual expected loss exceeding 217 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225505151.md"
description: "HUAPONT LIFE SCIENCES hit the daily limit down, reporting a price of 3.93 yuan, creating a new low in over 4 months, with a trading volume increasing to 263 million yuan and a total market value of 7.76 billion yuan. The company announced last Friday evening that the net profit attributable to shareholders of the listed company for 2024 is expected to be a loss of 310 million to 217 million yuan, compared to a profit of 302 million yuan in the same period last year, marking a year-on-year loss. During the reporting period, the goodwill generated from the acquisition of Baisheng Pharmaceutical still showed signs of impairment. In addition, the company's agricultural chemical new materials segment is affected by industry cyclicality, with some corresponding asset groups showing signs of impairment"
datetime: "2025-01-20T05:46:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225505151.md)
  - [en](https://longbridge.com/en/news/225505151.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225505151.md)
generator: "portal-rs"
---

# HUAPONT LIFE SCIENCES hit the limit down, reaching a new low in over 4 months, with an annual expected loss exceeding 217 million yuan

HUAPONT LIFE SCIENCES hit the limit down, reporting a price of 3.93 yuan, creating a new low in over 4 months, with a trading volume expanding to 263 million yuan and a total market value of 7.76 billion yuan. The company announced last Friday evening that the net profit attributable to shareholders of the listed company for 2024 is expected to be a loss of 310 million to 217 million yuan, compared to a profit of 302 million yuan in the same period last year, marking a year-on-year loss. During the reporting period, the goodwill generated from the acquisition of Baisheng Pharmaceutical still showed signs of impairment. In addition, the company's agricultural chemical new materials segment is affected by industry cyclicality, with some corresponding asset groups showing signs of impairment

### Related Stocks

- [002004.CN](https://longbridge.com/en/quote/002004.CN.md)
- [300758.CN](https://longbridge.com/en/quote/300758.CN.md)
- [000952.CN](https://longbridge.com/en/quote/000952.CN.md)
- [002648.CN](https://longbridge.com/en/quote/002648.CN.md)
- [300718.CN](https://longbridge.com/en/quote/300718.CN.md)
- [601137.CN](https://longbridge.com/en/quote/601137.CN.md)
- [03368.HK](https://longbridge.com/en/quote/03368.HK.md)
- [603125.CN](https://longbridge.com/en/quote/603125.CN.md)
- [00119.HK](https://longbridge.com/en/quote/00119.HK.md)
- [600346.CN](https://longbridge.com/en/quote/600346.CN.md)

## Related News & Research

- [QTTB: Promising phase II results for an IL-7/TSLP biologic in AA set the stage for pivotal trials](https://longbridge.com/en/news/299077020.md)
- [Tigermed Directors Face Regulatory Warning and Fines Over Disclosure Lapses](https://longbridge.com/en/news/298755822.md)
- [Vivesto’s Paccal Vet Shows Survival Benefit in Canine Hemangiosarcoma Study](https://longbridge.com/en/news/299046816.md)
- [MegaGen Announces Launch of BLUEDIAMOND ZYGOMA Implant at the 2026 NASM Symposium in Chicago](https://longbridge.com/en/news/299063618.md)
- [Applied Photonix Launches ViroZap®, the First FDA-Cleared Medical Device for In-Duct Air Disinfection](https://longbridge.com/en/news/299052227.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**